I
Immuneoncia Therapeutics
Specializing in drug development and antibody engineering
About Immuneoncia Therapeutics
ImmuneOncia is a biopharmaceutical company specializing in immuno-oncology, which involves using the body's immune system to fight cancer. Established in 2016 as a joint venture between Yuhan (51%) and Sorrento (49%), the company focuses on developing innovative immunotherapies designed to treat various types of cancer. ImmuneOncia operates in the highly competitive biopharmaceutical market, targeting healthcare providers, research institutions, and patients in need of advanced cancer treatments. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, licensing agreements, and sales of approved treatments. ImmuneOncia aims to make a significant impact on cancer treatment by offering therapies that enhance the body's natural ability to fight the disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 44.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | May 2025 | $24M | $24M | Undisclosed | ↗ |
| OtherOther financing | Dec 2021 | $0 | — | Welcome Capital | — |
Growth signals
Latest recorded traffic for Immuneoncia Therapeutics is 5.1K monthly website visits, down 30.1% over the last three months. Immuneoncia Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Repron TherapeuticsEpigenetic silencing platform for tumor recurrence repression |
Milan, Italy | Operational | 1 | $2.2M | $8.8M |
PrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy |
Jette, Belgium | Operational | |||
RayzeBioDefeating cancer with radiopharmaceutical medicines |
San Diego, United States | Acquired | |||
CellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer |
Óbidos, Portugal | Acquired | |||
ADCendoA Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers |
Copenhagen, Denmark | Operational | |||
Mediphage BioceuticalsCures for chronic diseases |
Toronto, Canada | Operational | |||
AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
| Durham, United States | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Immuneoncia Therapeutics in the Yongin-si ecosystem
The Immuneoncia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Paratus Investment
Other known investors4 additional known investors
- WCWelcome Capital
- DCDae Gyeong Investment Corporation
- E&E&Investment
Premier Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immuneoncia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immuneoncia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








